News and Events | 4TEEN4 Pharmaceuticals GmbH

About Us
4TEEN4 Pharmaceuticals Our target - Dipeptidyl Peptidase 3 Management Career Open Positions
DPP3
Dipeptidyl peptidase 3
Diagnostics
Diagnostics IB10 sphingotest^® DPP3
Therapy
Procizumab
News and Events
Funding

News and Events

All News Publication Event Press Release

No entries were found.

Company

Neuendorfstraße 15A, 16761 Hennigsdorf

+49 (0) 3302 205650

Navigation

News

» 4TEEN4’s first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis

» transkript: 4TEEN4's first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis

» Deniau B et al. on Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study

» News Medical: High DPP3 concentration in the blood predicts multiple organ failure in burn patients

Contact

I agree to the usage and progressing of my personal data.

© 2020 4TEEN4 Pharmaceuticals GmbH

Imprint / Impressum
Privacy Policy / Datenschutzerklärung